Insulin Binding to Antibodies is a Risk Factor for Inexplicable Severe Hypoglycaemia in Children with Type-1 Diabetes Mellitus[*]

Abstract

Background: Type-1 diabetic individuals differ with regard to both, the formation of circulating insulin antibodies, and the incidence of severe hypoglycaemia.

Aim of the study: To assess the association of insulin binding to antibodies with the incidence of severe hypoglycaemia.

Patients and methods: In a cross sectional study, 73 children with type-1 diabetes mellitus (median age 14 years, duration of diabetes 6 years) were investigated, 22 of whom had experienced severe hypoglycaemia during the past 18 months, and 51 had never experienced severe hypoglycaemia. Of the patients with severe hypoglycaemia 16 had experienced severe unexplained hypoglycaemias, and 6 had experienced severe hypoglycaemias which were explicable (by missed meals, unplanned physical exercise etc.). Insulin binding was measured in a blinded central laboratory by radioimmunoassay, and expressed as ratio bound/unbound insulin; a binding >15% was considered relevant insulin binding.

Results: A total of 38 patients displayed relevant insulin binding (17 of whom had experienced severe hypoglycaemia), and 35 patients did not (5 of whom had experienced severe hypoglycaemia; p=0.0055, Fisher's exact test). Patients with relevant insulin binding were younger (12.2 vs 14.5 years, p=0.006) than patients without relevant insulin binding. From the 16 patients with inexplicable severe hypoglycaemia, 15 displayed relevant insulin binding, compared to 2 of the 6 patients with explicable severe hypoglycaemia (p=0.009). The association of any severe hypoglycaemia, and of inexplicable severe hypoglycaemia, with relevant insulin binding was significant (odds ratio 4.8 (95%CI 1.5-15.2), and 22.1(95%CI 2.7-179.6), p<0.006). Patients with/without relevant insulin binding, or with/without severe hypoglycaemia, did not differ significantly regarding sex, duration of diabetes, number of insulin injections per day, HbA1c and C-peptide levels (ANOVA).

Conclusion: Insulin binding to antibodies >15% appears to be a strong risk factor for inexplicable severe hypoglycaemias in type-1 diabetic children.

Key words

autoimmunity - antibodies - diabetes

1 The study was presented in parts at the 43 rd EASD Annual Meeting 2007 in Amsterdam/The Netherlands, and at the 13th Annual Meeting of the ISPAD 2007 in Berlin /Germany.

References

• 1 Akram K, Pedersen-Bjergaard U, Carstensen B, Borch Johnsen K, Thorsteinsson B. Frequency and risk factors of severe hypoglycaemia in insulin-treated type-2 diabetes: a cross-sectional study.  Diabetic Med. 2006;  23 750-756
• 2 Bali C, Gurdet C, Irsigler K. Retrospective analysis on the incidence of severe hypoglycemia in 458 type-1 diabetics (Article in German).  Acta Med Austriaca. 1997;  24 165-169
• 3 Berson SA, Yalow RS. Studies with insulin-binding antibody.  Diabetes. 1957;  6 402-407
• 4 Bognetti A, Brunelli A, Meschi F, Viscardi M, Bonfanti R, Chiumello G. Frequency and correlates of severe hypoglycaemia in children and adolescents with diabetes mellitus.  Eur J Pediatr. 1997;  156 589-591
• 5 Bolli G, Feo P de, Compagnucci P, Cartechini MG, Angeletti G, Santeusiano F, Brunetti P, Gerich JE. Abnormal glucose counterregulation in insulin-dependent diabetes mellitus. Interaction of anti-insulin antibodies and impaired glucagon and epinephrine secretion.  Diabetes. 1983;  32 134-141
• 6 Bolli GB, Dimitriadis GD, Pehling GB, Baker BA, Haymond MW, Cryer PE, Gerich JE. Abnormal glucose counterregulation after subcutaneous insulin in insulin-dependent diabetes mellitus.  New Engl J Med. 1984;  310 1706-1711
• 7 Bott S, Bott U, Berger M, Mühlhauser I. Intensified insulin therapy and the risk of severe hypoglycaemia.  Diabetologia. 1997;  40 926-932
• 8 Bulsara MK, Holman CD, Davis EA, Jones TW. Evaluating risk factors associated with severe hypoglycaemia in epidemiologic studies - what method should we use?.  Diabet Med. 2004;  21 914-919
• 9 Bulsara MK, Holman CDJ, Davis EA, Jones TW. The impact of a decade of changing treatment on rates of severe hypoglycemia in a population-based cohort of children with type-1 diabetes.  Diabetes Care. 2004a;  27 2293-2298
• 10 Chantelau E, Seewi O, Sonnenberg GE, Heding LG, Berger M. Insulin antibodies and the use of insulin pumps.  Journal of Pediatric Endocrinology. 1985;  1 157-160
• 11 Chen JW, Frystyk J, Lauritzen T, Christiansen JS. Impact of insulin antibodies on insulin aspart pharmacokinetics and pharmacodynamics after 12-week treatment with multiple daily injections of biphasic insulin aspart 30 in patients with type-1 diabetes mellitus.  Eur J Endocrinol. 2005;  153 907-913
• 12 Christiansen AH. Radioimmunoelectrophoresis in the determination of insulin binding to IgG. Methodological studies.  Horm Metab Res. 1973;  5 147-154
• 13 Craig ME, Handelsman P, Donaghue KC, Chan A, Blades B, Laina R, Bradford D, Middlehurst A, Ambler G, Verge CF, Crock P, Moore P, Silink M. NSW/ACT HbA(1c) Study Group . Predictors of glycaemic control and hypoglycaemia in children and adolescents with type-1 diabetes from NSW and the ACT.  Med J Aust. 2002;  177 235-238
• 14 Cryer PE. Hypoglycaemia: the limiting factor in the glycaemic management of type-1 and type-2 diabetes.  Diabetologia. 2002;  45 937-948
• 15 DAFNE Study Group . Training in flexible, intensive insulin management to enable dietary freedom in people with type-1 diabetes: dose adjustment for normal eating (DAFNE) randomised controlled trial.  Br Med J. 2002;  325 746
• 16 Davis EA, Keating B, Byrne GC, Russell M, Jones TW. Hypoglycemia: incidence and clinical predictors in a large population-based sample of children and adolescents with IDDM.  Diabetes Care. 1997;  20 22-25
• 17 Davis EA, Keating B, Byrne GC, Russell M, Jones TW. Impact of improved glycaemic control on rates of hypoglycaemia in insulin dependent diabetes mellitus.  Arch Dis Child. 1998;  78 111-115
• 18 Beaufort CE De, Swift PG, Skinner CT. et al . Continuing stability of center differences in pediatric diabetes care : do advances in diabetes treatment improve outcome? The Hvidoere Study Group on Childhood Diabetes.  Diabetes Care. 2007;  30 2245-2250
• 19 Ege H, Heding LG. Prolongation and reduction of the effect of circulating insulin caused by insulin antibodies. In: P.Brunetti, KGMM Alberti, AM Albisser, KD Hepp, M Massi Benedetti (eds.) Artificial systems for insulin delivery. Serono Symposia Publications. 1983 6 Raven Press, New York 69-74
• 20 Egger M, Gschwend S, Smith GC, Zuppinger K. Increasing incidence of hypoglycemic coma in children with IDDM.  Diabetes Care. 1991;  14 1001-1005
• 21 Fineberg SE, Kawabata TT, Finco-Kent D, Fountaine RJ, Finch GL, Krasner AS. Immunological responses to exogenous insulin.  Endocrine Reviews. 2007;  28 625-652
• 22 Gonen B, Goldman Baldwin D, Goldberg RB, Ryan WG, Blix PM, Schanzlin D, Fritz KJ, Rubenstein AH. Metabolic control in diabetic patients. Effect of insulin secretory reserve (measured by plasma c-peptide) and circulating insulin antibodies.  Diabetes. 1979;  28 749-753
• 23 Home PD. Intensive insulin therapy in clinical practice.  Diabetologia. 1997;  40 ((2)) S83-S87
• 24 Heller S, Chapman J, MacCloud J, Ward J. Unreliability of reports of hypoglycaemia by diabetic patients.  Br Med J. 1995;  310 440
• 25 Jaeger C, Eckhard M, Brendel MD, Bretzel RG. Diagnostic algorithm and management of immune-mediated complications associated with subcutaneous insulin therapy.  Exp Clin Endocrinol Diabetes. 2004;  112 416-421
• 26 Kimmerle R, Heinemann L, Delecki A, Berger M. Severe hypoglycemia incidence and predisposing factors in 85 pregnancies of type-1 diabetic women.  Diabetes Care. 1992;  15 1034-1037
• 27 Limbert C, Schwingshandl J, Haas J, Roth R, Borkenstein M. Severe hypoglycemia in children and adolescents with IDDM: frequency and associated factors.  J Diabetes Complications. 1993;  7 216-220
• 28 Mianowska B, Heinrich A, Bodalski J. Severe hypoglycemia in type-1 diabetic children and adolescents-assessment of frequency and quest for predisposing factors. Abstract.  Diabetologia. 2003;  46 ((2)) A33-2: A34
• 29 Mianowska B, Perenc M, Heinrich A, Bodalski J. Severe hypoglycemia and insulin antibodies levels in children and adolescents with type-1 diabetes (in Polish).  Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw. 2003a;  9 29-34
• 30 Mühlhauser I, Toth G, Sawicki PT, Berger M. Severe hypoglycemia in type-1 diabetic patients with impaired kidney function.  Diabetes Care. 1991;  14 344-346
• 31 Pedersen-Bjergaard U, Pramming S, Heller SR, Wallace TM, Rasmussen AK, Jorgensen HV, Matthews DR, Hougaard P, Thorsteinsson B. Severe hypoglycaemia in 1076 adult patients with type-1 diabetes: influence of risk markers and selection.  Diabetes Metab Res Rev. 2004;  20 479-486
• 32 Renard E, Schaepelynck-Belicar P. EVADIAC Group . Implantable insulin pumps. A position statement about their clinical use.  Diabetes Metab. 2007;  33 158-166
• 33 Rewers A, Chase HP, Mackenzie T, Walravens P, Roback M, Rewers M, Hamman RF, Klingensmith G. Predictors of acute complications in children with type-1 diabetes mellitus.  JAMA. 2002;  287 2511-2518
• 34 Ryan C, Gurtunca N, Becker D. Hypoglycemia: a complication of diabetes therapy in children.  Pediatr Clin North Am. 2005;  52 1705-1733
• 35 Scheepker A, Schröter W, Nauck MA. Characterisation of patients with type-1 diabetes treated with insulin Depot CR or CS twice daily until the years 2002/2003(in German).  Diabetologie und Stoffwechsel. 2007;  2 94-101
• 36 The DCCT Research Group . The Diabetes control and complications trial (DCCT): update.  Diabetes Care. 1990;  13 427-433
• 37 The DCCT Research Group . Epidemiology of severe hypoglycemia in the Diabetes Control and Complications Trial.  Am J Med. 1991;  90 450-459
• 38 The DCCT Research Group . Hypoglycemia in the Diabetes Control and Complications Trial.  Diabetes. 1997;  46 271-286
• 39 Tupola S, Rajantie J, Maenpaa J. Severe hypoglycaemia in children and adolescents during multi-dose insulin therapy.  Diabetic Med. 1998;  15 695-699
• 40 Van Haeften TW. Clinical significance of insulin antibodies in insulin-treated diabetic patients.  Diabetes Care. 1989;  12 641-648
• 41 Van Haeften TW, Heiling VJ, Gerich JE. Adverse effects of insulin antibodies on postprandial plasma glucose and insulin profiles in diabetic patients without immune insulin resistance. Implications for intensive insulin regimens.  Diabetes. 1987;  36 305-309
• 42 Wagner VM, Grabert M, Holl RW. Severe hypoglycaemia, metabolic control and diabetes management in children with type-1 diabetes in the decade after the Diabetes Control and Complications Trial- a large-scale multicentre study.  Eur J Pediatr. 2005;  164 73-79
• 43 Wagner V, Rosenbauer J, Grabert M, Holl RW. Severe hypoglycaemia, metabolic control and diabetes management in young children with type-1 diabetes using insulin analogs-a follow up report of a large multicenter data base.  Eur J Pediatr. 2008;  167 241-242
• 44 Wredling R, Lins PE, Adamson U. Prevalence of anti-insulin antibodies and its relation to severe hypoglycaemia in insulin-treated diabetic patients.  Scand J Clin Lab Invest. 1990;  50 551-557

1 The study was presented in parts at the 43 rd EASD Annual Meeting 2007 in Amsterdam/The Netherlands, and at the 13th Annual Meeting of the ISPAD 2007 in Berlin /Germany.

Correspondence